Feb 4- Research services provider Covance Inc reported a better-than-expected 19 percent jump in quarterly adjusted profit as it gained from higher investments in later stages of drug development by pharma companies.
*Raises 2013 profit forecast to $2.03- $2.09/ share from $1.95- $2.05. Oct 31- Quintiles Transnational Holdings Inc, the world's largest medical contract research provider, raised its full-year earnings forecast after reporting a higher-than-expected quarterly profit due to more contract wins.
Oct 30- Parexel International Corp's shares fell as much as 18 percent after the drug research services provider said it struggled to win new contracts when rivals reported strong results and raised their forecasts.
Is there a way to profit from small cap biotech without being at the mercy of the FDA's drug approval process? Maybe.
Oct 4- Charles River Laboratories:. *Knight Equity starts Charles River Laboratories with buy; price. Reuters Station users, click. 1568.
Barry Rosenstein, founder of Jana Partners, is best known as an activist investor. The hedge fund manager made intriguing moves in the fourth quarter, buying more shares of Apple and making an outsized bet on Marathon Petroleum.
Shares of the following companies are showing unusual moves in Tuesday's trading session.
Who says nothing of importance happened on Thursday? Plus, a call on Lululemon Athletica.
Today's mergers and acquisitions environment is very complex, moving away from a board-centric model towards a more shareholder-based system, especially in the United States and other Western nations.
Herein are Thursday's biggest winners and losers. Find out why shares of Fortune Brands popped while Arena Pharmaceuticals dropped.
A sugary treat to weather the sour market swings.
In the latest move in the big pharma restructuring/outsourcing trend, Eli Lilly announced this morning that it's selling a lab site in its home state of Indiana to the contract research organization Covance.
The old adage advises investors to "sell in may and go away," but CNBC asked the experts for stock picks that might that might make investors stay in the game this month.
Recent gains in the markets have changed the valuation picture on a lot of stocks, but Jefferies managing director Art Hogan is constantly on the lookout for bargains, and he told CNBC about some stocks that are still steals.
To politicians, railing against it brings votes. To companies, it cuts costs. But to Cramer, it’s a chance to make Homegamers some mad money.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Okay, the real "Granddaddy of 'em all" was actually this past Tuesday at the Rose Bowl (I promise that's my last reference to the amazing USC Trojans unless they win a split national championship), but the granddaddy of healthcare investment conferences begins on Monday in San Francisco.
Here's our weekly web cast in case you missed it. Every Monday at 12 pm EST, CNBC's Dylan Ratigan hosts a web program on the contest. He had Art Hogan from Jefferies on to talk about Art's stock picks for the contest. Art's adding some, keeping others, but removing one. Again--his picks are for the contest and NOT for personal investing. Also, here are the leaderboard standings from Thursday's action.